You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Haleraid is a non-powered device designed to help patients with impaired hand agility (e.g. due to arthritis, muscle weakness) administer aerosol medication from a metered dose inhaler (MDI). It is in the form of a plastic housing within which the MDI is placed, and which facilitates the manual actuation of the MDI, using leverage. Haleraid is a device developed to help patients with impaired hand agility administer GSK’s Seretide (salmeterol xinafoate /fluticasone propionate), Serevent (salmeterol), Flixotide (fluticasone Propionate) and Ventolin (salbutamol) 200 and 120 dose Evohalers. This is a reusable device.

Discontinuation of Haleraid globally

Following a considered review with our manufacturing partner, GSK made a global decision to discontinue Haleraid 200 dose and Haleraid 120 dose. It is now discontinued in all countries.

This is a reusable device and patients can continue to use the Haleraid devices that they have as normal. For any alternatives, patients should discuss these with their healthcare provider.

[Haleraid] is a registered trademark of the GlaxoSmithKline group of companies

Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.